Clinical Trials Logo

Pulmonary Eosinophilia clinical trials

View clinical trials related to Pulmonary Eosinophilia.

Filter by:

NCT ID: NCT05787678 Recruiting - Clinical trials for Asthma; Eosinophilic

Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion

DEBORA
Start date: October 1, 2023
Phase:
Study type: Observational

Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics (small airway dysfunction and mucin production) in uncontrolled severe asthma patients in the real life setting without control group

NCT ID: NCT05763121 Recruiting - Asthma Clinical Trials

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

EXHALE-2
Start date: January 30, 2023
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.

NCT ID: NCT05762627 Not yet recruiting - Asthma in Children Clinical Trials

Severe Eosinophilic Asthma Phenotypes During Childhood Have Various Origins

SAMP 2
Start date: March 2023
Phase:
Study type: Observational

Study of the clinical evolution at 10 years of children from the SAMP cohort (severe asthma, eosinophilic or not, allergic or not) in order to understand the different possible evolutions of these phenotypes at different ages.

NCT ID: NCT05748600 Recruiting - Clinical trials for Asthma; Eosinophilic

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

EXHALE-4
Start date: January 30, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.

NCT ID: NCT05734339 Active, not recruiting - Asthma Clinical Trials

Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)

Start date: January 19, 2023
Phase:
Study type: Observational

An open-label, single-arm, non-interventional, prospective, multicenter study involving primary data collection within real-world settings for patients who receive benralizumab for treatment of severe uncontrolled eosinophilic asthma

NCT ID: NCT05692180 Recruiting - Asthma Clinical Trials

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

DOMINICA
Start date: April 5, 2023
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patients ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.

NCT ID: NCT05603845 Active, not recruiting - Severe Asthma Clinical Trials

Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

iOUTRUN
Start date: February 20, 2023
Phase:
Study type: Observational

This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia, Kuwait, United Arab Emirates, Oman, and Qatar), Latin America (Brazil, Argentina, and Colombia), and India. It is anticipated that the data generated will provide practical, patient-focused real-world evidence and enhance communications between patients and physicians in an objective and structured manner to ensure better disease control in patients under benralizumab treatment.

NCT ID: NCT05584306 Active, not recruiting - Asthma Clinical Trials

A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma

Start date: December 6, 2021
Phase: Phase 1
Study type: Interventional

This study will assess the safety, tolerability, pharmacokinetics and preliminary efficacy of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

NCT ID: NCT05552508 Active, not recruiting - Asthma Clinical Trials

BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging

BURAN
Start date: October 11, 2022
Phase: Phase 4
Study type: Interventional

This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.

NCT ID: NCT05528679 Not yet recruiting - Asthma Clinical Trials

A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma

Start date: September 2022
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.